198 related articles for article (PubMed ID: 16925897)
1. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
Manavi K; Scott G
Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
[TBL] [Abstract][Full Text] [Related]
2. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
3. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
4. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
7. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
9. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
[TBL] [Abstract][Full Text] [Related]
10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
12. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
Ségéral O; Limsreng S; Nouhin J; Hak C; Ngin S; De Lavaissière M; Goujard C; Taburet AM; Nerrienet E; Delfraissy JF; Ouk V; Dulioust A
AIDS Res Hum Retroviruses; 2011 Jun; 27(6):597-603. PubMed ID: 21083413
[TBL] [Abstract][Full Text] [Related]
13. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
15. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
16. Comparative potency of three antiretroviral therapy regimes in primary HIV infection.
Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J
AIDS; 2006 Jan; 20(2):247-52. PubMed ID: 16511418
[TBL] [Abstract][Full Text] [Related]
17. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
18. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
19. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
20. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Metzner KJ; Allers K; Rauch P; Harrer T
AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
